HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

REACH

This article was originally published in The Rose Sheet

Executive Summary

European Parliament completes first reading of proposed Registration, Evaluation and Authorization of Chemicals system. Legislative package was adopted by a vote of 407 to 155, with 41 abstentions, on Nov. 17. REACH would require producers of more than one ton of a chemical substance to register with a future chemicals agency. Proposal recently was amended by the Environment Committee to ease registration requirements for chemicals produced in quantities between one and 10 tons. During the first reading, parliament members reached a number of compromises on the proposal, including a possible waiver of certain tests for substances produced or imported between 10 and 100 tons. The European Council must next reach a common position on REACH, the parliament notes, adding that step is expected by year-end...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS013537

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel